Glancy Binkow & Goldberg LLP announces that a class action complaint has been filed with an expanded Class Period in the shareholder lawsuit pending in the United States District Court for the District of New Jersey against Aeterna Zentaris Inc. (“Aeterna” or the “Company”) (NASDAQ:AEZS). The complaint alleges violations of federal securities laws and asserts claims on behalf of purchasers of Aeterna securities between April 2, 2012 and November 6, 2014, inclusive (the “Class Period”).

Aeterna is a specialty biopharmaceutical company engaged in the development and commercialization of novel treatments in oncology and endocrinology. The Company is developing macimorelin − an orally active small molecule that stimulates the secretion of growth hormone − as a treatment for Adult Growth Hormone Deficiency. The lawsuit alleges that defendants misrepresented or failed to disclose that: (1) the planned analysis of macimorelin’s pivotal clinical trial failed to meet its primary efficacy endpoint pursuant to the Special Protocol Assessment agreement letter between the Company and the FDA; (2) insufficient data existed to confirm that the patients in the clinical trial were accurately diagnosed with Adult Growth Hormone Deficiency; (3) a serious cardiac event could have been attributed to macimorelin; (4) as a result, the FDA would not approve the New Drug Application for macimorelin in its present form; and (5), the Company’s statements about its business, operations and prospects, including statements about macimorelin’s prospects for FDA approval, were materially false and misleading and/or lacked a reasonable basis.

If you purchased Aeterna securities between April 2, 2012 and November 6, 2014, you may move the Court no later than January 12, 2015, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at 888-773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Binkow & Goldberg LLP, Los AngelesCasey Sadler, 310-201-9150 or 888-773-9224shareholders@glancylaw.comwww.glancylaw.com

Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Aeterna Zentaris Charts.
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Aeterna Zentaris Charts.